Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van Der Meer P, et al. Cardio-oncology services: rationale, organization, and implementation. Eur Heart J. 2019;40(22):1756–63. https://doi.org/10.1093/eurheartj/ehy453.

Article  PubMed  Google Scholar 

Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, et al. A synopsis of the evidence for the science and clinical management of Cardiovascular-Kidney-Metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023;148(20):1636–64. https://doi.org/10.1161/cir.0000000000001186.

Article  PubMed  Google Scholar 

Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148(20):1606–35. https://doi.org/10.1161/cir.0000000000001184.

Article  PubMed  Google Scholar 

Brady B, Brown A, Barrett M, Maraj V, Lawler F, Murphy R, Walsh D. Cardiac dysfunction in solid tumours: scoping review. BMJ Support Palliat Care. 2023; spcare-2023-004. https://doi.org/10.1136/spcare-2023-004440.

Article  Google Scholar 

Moore TB, Streja L, Kempert P, Ikeda A, Venick K, Kwak M, et al. Obesity in survivors of childhood hematopoietic stem cell transplantation. Blood. 2008;112(11):2130. https://doi.org/10.1182/blood.v112.11.2130.2130.

Article  Google Scholar 

Tan J, Barmanray R, Cirone B, Klarica D, Russell A, Spencer A, Wright T. Cardiovascular and metabolic risk incidence among adult allogeneic stem cell transplant recipients: a narrative review. Transplant Cell Ther. 2024. https://doi.org/10.1016/j.jtct.2024.07.014.

Article  PubMed  PubMed Central  Google Scholar 

Attachaipanich T, Chattipakorn S, Chattipakorn N. Cardiovascular toxicities by calcineurin inhibitors: cellular mechanisms behind clinical manifestations. Acta Physiol. 2024. https://doi.org/10.1111/apha.14199.

Article  Google Scholar 

Alblooshi R, Kanfar S, Lord B, Atenafu EG, Michelis FV, Pasic I, et al. Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant. Eur J Haematol. 2021;106(1):32–9. https://doi.org/10.1111/ejh.13482.

Article  PubMed  CAS  Google Scholar 

Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international Cardio-Oncology society (IC-OS). Eur Heart J. 2022;43(41):4229–361. https://doi.org/10.1093/eurheartj/ehac244.

Article  PubMed  Google Scholar 

Liu D, Weintraub MA, Garcia C, Goncalves MD, Sisk AE, Casas A, et al. Characterization, management, and risk factors of hyperglycemia during < scp > PI3K or < scp > akt inhibitor treatment. Cancer Med. 2022;11(8):1796–804. https://doi.org/10.1002/cam4.4579.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bays HE. Adiposopathy is sick fat a cardiovascular disease? J Am Coll Cardiol. 2011;57(25):2461–73. https://doi.org/10.1016/j.jacc.2011.02.038.

Article  PubMed  CAS  Google Scholar 

Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009;181(5):1998–2008. https://doi.org/10.1016/j.juro.2009.01.047.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Choi SM, Kam SC. Metabolic effects of androgen deprivation therapy. Korean J Urol. 2015;56(1):12. https://doi.org/10.4111/kju.2015.56.1.12.

Article  PubMed  PubMed Central  Google Scholar 

Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, Finkelstein JS. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer. Cancer. 2008;112(10):2188–94. https://doi.org/10.1002/cncr.23440.

Article  PubMed  CAS  Google Scholar 

Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87(2):599–603. https://doi.org/10.1210/jcem.87.2.8299.

Article  PubMed  CAS  Google Scholar 

Swaby JD, Aggarwal A, Batra A, Jain A, Seth L, Stabellini N, et al. Abstract 12761: association of androgen deprivation therapy with metabolic disease in prostate cancer patients: an updated Meta-Analysis. Circulation. 2022;146(Suppl1). https://doi.org/10.1161/circ.146.suppl_1.12761.

Keating NL, Liu P-H, O’Malley AJ, Freedland SJ, Smith MR. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol. 2014;65(4):816–24. https://doi.org/10.1016/j.eururo.2013.02.023.

Article  PubMed  CAS  Google Scholar 

Chi JT, Lin PH, Tolstikov V, Oyekunle T, Chen EY, Bussberg V, et al. Metabolomic effects of androgen deprivation therapy treatment for prostate cancer. Cancer Med. 2020;9(11):3691–702. https://doi.org/10.1002/cam4.3016.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rana MN, Neeland IJ. Adipose tissue inflammation and cardiovascular disease: an update. Curr Diab Rep. 2022;22(1):27–37. https://doi.org/10.1007/s11892-021-01446-9.

Article  PubMed  CAS  Google Scholar 

Wu Y-H, Jhan J-H, Ke H-L, Tseng S-I, Chang Y-H, Yeh H-C, et al. Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study. Int J Clin Pharm. 2020;42(6):1433–9. https://doi.org/10.1007/s11096-020-01143-9.

Article  PubMed  CAS  Google Scholar 

Wilson RL, Taaffe DR, Newton RU, Hart NH, Lyons-Wall P, Galvão DA. Using exercise and nutrition to alter fat and lean mass in men with prostate cancer receiving androgen deprivation therapy: a narrative review. Nutrients. 2021;13(5):1664. https://doi.org/10.3390/nu13051664.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Freedland SJ, Howard L, Allen J, Smith J, Stout J, Aronson W, et al. A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial. Prostate Cancer Prostatic Dis. 2019;22(3):428–37. https://doi.org/10.1038/s41391-019-0126-5.

Article  PubMed  CAS  Google Scholar 

Scott JM, Li N, Liu Q, Yasui Y, Leisenring W, Nathan PC, et al. Association of exercise with mortality in adult survivors of childhood cancer. JAMA Oncol. 2018;4(10):1352. https://doi.org/10.1001/jamaoncol.2018.2254.

Article  PubMed  PubMed Central  Google Scholar 

Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, et al. Nutrition and physical activity guidelines for cancer survivors. Cancer J Clin. 2012;62(4):242–74. https://doi.org/10.3322/caac.21142.

Article  Google Scholar 

Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337. https://doi.org/10.1093/eurheartj/ehab484.

Article  PubMed  Google Scholar 

9. Pharmacologic approaches to glycemic treatment: standards of care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S158–78. https://doi.org/10.2337/dc24-S009.

Article  Google Scholar 

Page P MR. The JNC 8 hypertension guidelines: an in-depth guide. Am J Manag Care. 2014;20(1 Spec No):E8.

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: A report of the American college of cardiology/american heart association task force on clinical practice guidelines. Circulation. 2019;140(11). https://doi.org/10.1161/cir.0000000000000677.

Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with Tamoxifen versus Tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359(9324):2131–9. https://doi.org/10.1016/s0140-6736(02)09088-8.

Article  PubMed  CAS  Google Scholar 

Breast International Group 1, –, 98, Collaborative G, Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747–57. https://doi.org/10.1056/NEJMoa052258.

Article  Google Scholar 

Goldvaser H, Barnes TA, Seruga B, Cescon DW, Ocana A, Ribnikar D, Amir E. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: A systematic review and Meta-analysis. J Natl Cancer Inst. 2018;110(1). https://doi.org/10.1093/jnci/djx141.

Khosrow-Khavar F, Filion K, Bouganim N, Suissa S, Azoulay L. Aromatase inhibitors and the risk of cardiovascular outcomes in women with. Breast Cancer. 2020;141:549–59. https://doi.org/10.1161/CIRCULATIONAHA.119.044750.

Article